Patello-Femoral Joint Post Market Clinical Follow-up Within the Knee Registry (PFJPMCF)

Inclusion Criteria:

• Patient is greater than 18 years of age;
• Patient selection is without bias to race or gender;
• Patient is in stable health and able to undergo surgery;

• Patient has patellofemoral joint(s) affected by disease process and/or injury and qualifying for primary unilateral or bilateral replacement of the femoral trochlea based a primary diagnosis of at least one of the following:

  • Osteoarthritis
  • Traumatic Arthritis
  • Polyarthritis
  • Severe Chondrocalcinosis
  • Salvage of previously failed surgical attempts (e.g., arthroscopy, lateral release, cartilage transplantation)
  • History of patellar dislocation or patella fracture
  • Dysplasia-induced patellofemoral degeneration
• Patient is willing and able to cooperate in prescribed post-operative therapy;
• Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent;
• Patient has participated in the Informed Consent process and has signed an IRB approved Informed Consent.
• Patient has not history of previous prosthetic replacement device(s) of any type in the affected knee joint;
• Independent of study participation, patient is scheduled to receive treatment using a Zimmer Gender Solutions Patellofemoral Joint Prosthesis (PFJ).

Exclusion Criteria:

• Patient with an acute, chronic, local or systemic infection;
• Patient is skeletally immature;
• Patient is pregnant;
• Patient is a prisoner, mentally incompetent or anticipated to be non-compliant. Patient has a known allergy to one of the constituents of the implant, e.g. cobalt, chromium, nickel, etc.;
• Patient has Rheumatoid Arthritis (RA) AND an ulcer of the skin OR a history of recurrent breakdown of the skin;
• Patient has neuropathic arthropathy, neuromuscular disorder, neurologic condition, vascular disorder, systemic disease and/or other condition that affects lower limb function and/or could contribute to prosthesis instability, prosthesis fixation failure, and/or complications in postoperative care;
• Patient has a Body Mass Index (BMI) greater than 40;
• Patient has insufficient native bone stock in the operative joint (e.g. osteoporosis, osteonecrosis, tumors, cysts, etc.). Note: Bone void fillers are NOT considered native bone stock, even if autograft is used;
• Patient has severe instability, maltracking, or malalignment of the patella, patellofemoral, and/or tibiofemoral joints;
• Patient has patellectomy of the affected joint, including previous patellectomy, patellectomy performed simultaneous to study PFA, or scheduled patellectomy;
• Patient has insufficient menisci and/or ligament structures (e.g. non-functional/absent ACL and/or PCL);

• Patient exhibits tibiofemoral degeneration and/or Outerbridge grade greater than or equal to 3 in EITHER:

  • one (medial or lateral) tibiofemoral compartment that is not treated with a simultaneous compatible Zimmer unicompartmental knee replacement; OR
  • both (medial AND lateral) tibiofemoral compartments, regardless of treatment.